Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Lonafarnib CAS 193275-84-2

Lonafarnib CAS 193275-84-2

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 193275-84-2

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
193275-84-2
Appearance::
White To Beige Powder
Molecular Formula::
C27H31Br2ClN4O2
Molecular Weight::
638.82200
EINECS NO::
679-527-9
MDL NO::
MFCD06795138
CAS NO::
193275-84-2
Appearance::
White To Beige Powder
Molecular Formula::
C27H31Br2ClN4O2
Molecular Weight::
638.82200
EINECS NO::
679-527-9
MDL NO::
MFCD06795138
Lonafarnib CAS 193275-84-2

Product Description:

Product Name: Lonafarnib CAS NO: 193275-84-2

 

 

 

Synonyms:

1-PiperidinecarboxaMide,4-[2-[4-[(11R)-3,10-dibroMo-8-chloro-6;

[14C]-Lonafarnib;

 

 

 

Chemical & Physical Properties:

Appearance: White to beige powder

Assay :≥99.0%

Density: 1.536

Storage Temp.: -20℃

Flash Point: 383.5℃

Boiling Point: 710.4℃ at 760mmHg

Melting point: 214.5-215.9° (monohydrate); mp 222-223°

 

 

 

Safety Information:

Caution Statement: P305 + P351 + P338

Symbol: GHS07

Signal Word: Warning

Hazard Declaration: H315; H319; H335

 

 

 

Lonafarnib is a farnesyltransferase inhibitor (FTI) that is being investigated in a human clinical trial as a potential treatment for progeria.

Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. As such, it is used primarily for cancer treatment. For those with progeria, research has shown that the drug reduces the prevalence of stroke and transient ischemic attack, and the prevalence and frequency of headaches while taking the medication. A phase II clinical trial was completed in 2012, which showed that a cocktail of drugs that included lonafarnib and two other drugs, met clinical efficacy endpoints that improved the height and diminished the rigidity of the bones of progeria patients.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.